Free Trial

Vaxcyte, Inc. (NASDAQ:PCVX) Stock Holdings Lowered by Perceptive Advisors LLC

Vaxcyte logo with Medical background

Perceptive Advisors LLC trimmed its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 18.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,088,486 shares of the company's stock after selling 254,265 shares during the quarter. Vaxcyte makes up 1.5% of Perceptive Advisors LLC's investment portfolio, making the stock its 20th largest position. Perceptive Advisors LLC owned approximately 1.14% of Vaxcyte worth $68,357,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of PCVX. Westfield Capital Management Co. LP purchased a new position in shares of Vaxcyte in the 3rd quarter valued at $51,180,000. Norges Bank purchased a new position in Vaxcyte during the 4th quarter worth $57,494,000. Vestal Point Capital LP purchased a new position in Vaxcyte during the 4th quarter worth $32,970,000. Eventide Asset Management LLC purchased a new position in Vaxcyte during the 3rd quarter worth $20,035,000. Finally, First Turn Management LLC purchased a new position in Vaxcyte during the 4th quarter worth $22,453,000. 96.78% of the stock is owned by hedge funds and other institutional investors.

Vaxcyte Price Performance

Shares of PCVX stock traded down $1.07 during mid-day trading on Friday, hitting $72.94. The stock had a trading volume of 347,440 shares, compared to its average volume of 495,876. Vaxcyte, Inc. has a fifty-two week low of $44.20 and a fifty-two week high of $82.04. The firm has a market cap of $7.94 billion, a PE ratio of -17.04 and a beta of 0.97. The company's 50-day simple moving average is $67.24 and its 200-day simple moving average is $66.69.


Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its earnings results on Wednesday, May 8th. The company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($1.13) by $0.28. On average, analysts expect that Vaxcyte, Inc. will post -3.96 EPS for the current year.

Analyst Ratings Changes

Several research analysts have issued reports on the stock. Cantor Fitzgerald reissued an "overweight" rating on shares of Vaxcyte in a research report on Thursday, May 9th. Needham & Company LLC reissued a "buy" rating and set a $95.00 price objective on shares of Vaxcyte in a research report on Thursday, May 9th.

Read Our Latest Stock Analysis on PCVX

Insider Activity at Vaxcyte

In related news, SVP Mikhail Eydelman sold 1,667 shares of the firm's stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $72.06, for a total value of $120,124.02. Following the completion of the sale, the senior vice president now owns 31,161 shares in the company, valued at $2,245,461.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, SVP Mikhail Eydelman sold 1,667 shares of the firm's stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $72.06, for a total value of $120,124.02. Following the completion of the sale, the senior vice president now owns 31,161 shares in the company, valued at $2,245,461.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Andrew Guggenhime sold 8,000 shares of the firm's stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $69.02, for a total transaction of $552,160.00. Following the completion of the sale, the chief financial officer now owns 95,679 shares of the company's stock, valued at approximately $6,603,764.58. The disclosure for this sale can be found here. Insiders sold 94,483 shares of company stock worth $6,469,643 over the last 90 days. Company insiders own 3.10% of the company's stock.

About Vaxcyte

(Free Report)

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

Recommended Stories

Institutional Ownership by Quarter for Vaxcyte (NASDAQ:PCVX)

Should you invest $1,000 in Vaxcyte right now?

Before you consider Vaxcyte, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.

While Vaxcyte currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

CPI News Breakdown: Key Market Moves to Follow
Understanding Oversold Stocks
Inside Pelosi’s Latest Stock Moves

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines